Colin B Begg

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8987022/publications.pdf

Version: 2024-02-01

181 papers	23,554 citations	13068 68 h-index	7496 151 g-index
185 all docs	185 docs citations	185 times ranked	22780 citing authors

#	Article	IF	Citations
1	Improving the Quality of Reporting of Randomized Controlled Trials. JAMA - Journal of the American Medical Association, 1996, 276, 637.	3.8	2,759
2	Prognostic effect of weight loss prior tochemotherapy in cancer patients. American Journal of Medicine, 1980, 69, 491-497.	0.6	2,161
3	Impact of Hospital Volume on Operative Mortality for Major Cancer Surgery. JAMA - Journal of the American Medical Association, 1998, 280, 1747.	3.8	1,496
4	Racial Differences in the Treatment of Early-Stage Lung Cancer. New England Journal of Medicine, 1999, 341, 1198-1205.	13.9	944
5	Variations in Morbidity after Radical Prostatectomy. New England Journal of Medicine, 2002, 346, 1138-1144.	13.9	800
6	Probabilistic Sensitivity Analysis Using Monte Carlo Simulation. Medical Decision Making, 1985, 5, 157-177.	1.2	757
7	Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 1999, 17, 2745-2745.	0.8	716
8	The Influence of Hospital Volume on Survival after Resection for Lung Cancer. New England Journal of Medicine, 2001, 345, 181-188.	13.9	656
9	Variations in Lung Cancer Risk Among Smokers. Journal of the National Cancer Institute, 2003, 95, 470-478.	3.0	547
10	Computed Tomography Screening and Lung Cancer Outcomes. JAMA - Journal of the American Medical Association, 2007, 297, 953.	3.8	490
11	Biases in the assessment of diagnostic tests. Statistics in Medicine, 1987, 6, 411-423.	0.8	487
12	Age and Adjuvant Chemotherapy Use After Surgery for Stage III Colon Cancer. Journal of the National Cancer Institute, 2001, 93, 850-857.	3.0	450
13	Survival of Blacks and Whites After a Cancer Diagnosis. JAMA - Journal of the American Medical Association, 2002, 287, 2106.	3.8	444
14	Prognostic factors in differentiated carcinoma of the thyroid gland. American Journal of Surgery, 1992, 164, 658-661.	0.9	364
15	Variations Among Individual Surgeons in the Rate of Positive Surgical Margins in Radical Prostatectomy Specimens. Journal of Urology, 2003, 170, 2292-2295.	0.2	311
16	Hospital and Surgeon Procedure Volume as Predictors of Outcome Following Rectal Cancer Resection. Annals of Surgery, 2002, 236, 583-592.	2.1	306
17	Cancer Survivorshipâ€"Genetic Susceptibility and Second Primary Cancers: Research Strategies and Recommendations. Journal of the National Cancer Institute, 2006, 98, 15-25.	3.0	295
18	Clinical trials and drug toxicity in the elderly. The experience of the eastern cooperative oncology group. Cancer, 1983, 52, 1986-1992.	2.0	282

#	Article	IF	Citations
19	The Effect of Clustering of Outcomes on the Association of Procedure Volume and Surgical Outcomes. Annals of Internal Medicine, 2003, 139, 658.	2.0	280
20	A General Regression Methodology for ROC Curve Estimation. Medical Decision Making, 1988, 8, 204-215.	1.2	249
21	Role of video-assisted thoracic surgery in the treatment of pulmonary metastases: Results of a prospective trial. Annals of Thoracic Surgery, 1996, 62, 213-217.	0.7	244
22	Variation of Breast Cancer Risk Among BRCA1/2 Carriers. JAMA - Journal of the American Medical Association, 2008, 299, 194-201.	3.8	244
23	Calculation of Polychotomous Logistic Regression Parameters Using Individualized Regressions. Biometrika, 1984, 71, 11.	1.3	233
24	Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study. Journal of Clinical Oncology, 2013, 31, 4252-4259.	0.8	232
25	Breast Cancer After Chest Radiation Therapy for Childhood Cancer. Journal of Clinical Oncology, 2014, 32, 2217-2223.	0.8	230
26	Adjuvant Chemotherapy Use for Medicare Beneficiaries With Stage II Colon Cancer. Journal of Clinical Oncology, 2002, 20, 3999-4005.	0.8	226
27	Resurrecting Treatment Histories of Dead Patients. JAMA - Journal of the American Medical Association, 2004, 292, 2765.	3.8	220
28	Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection. Journal of Surgical Oncology, 2003, 83, 68-78.	0.8	202
29	Lifetime Risk of Melanoma in CDKN2A Mutation Carriers in a Population-Based Sample. Journal of the National Cancer Institute, 2005, 97, 1507-1515.	3.0	200
30	Variation of Serum Prostate-Specific Antigen Levels. JAMA - Journal of the American Medical Association, 2003, 289, 2695.	3.8	198
31	VARIATIONS AMONG HIGH VOLUME SURGEONS IN THE RATE OF COMPLICATIONS AFTER RADICAL PROSTATECTOMY: FURTHER EVIDENCE THAT TECHNIQUE MATTERS. Journal of Urology, 2005, 173, 2099-2103.	0.2	190
32	Prognostic factors for recurrence and survival in head and neck soft tissue sarcomas. Cancer, 1994, 74, 697-702.	2.0	188
33	On the Use of Familial Aggregation in Population-Based Case Probands for Calculating Penetrance. Journal of the National Cancer Institute, 2002, 94, 1221-1226.	3.0	182
34	Number of Nevi and Early-Life Ambient UV Exposure Are Associated with BRAF-Mutant Melanoma. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 991-997.	1.1	180
35	Is Trichomonas vaginalis a Cause of Cervical Neoplasia? Results from a Combined Analysis of 24 Studies. International Journal of Epidemiology, 1994, 23, 682-690.	0.9	179
36	Population-Based Study of the Risk of Second Primary Contralateral Breast Cancer Associated With Carrying a Mutation inBRCA1orBRCA2. Journal of Clinical Oncology, 2010, 28, 2404-2410.	0.8	166

#	Article	IF	Citations
37	Association BetweenNRASandBRAFMutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma. JAMA Oncology, 2015, 1, 359.	3.4	164
38	Genomic and Mutational Profiling to Assess Clonal Relationships Between Multiple Nonâ€“Small Cell Lung Cancers. Clinical Cancer Research, 2009, 15, 5184-5190.	3.2	151
39	Who Gets Adjuvant Treatment for Stage II and III Rectal Cancer? Insight From Surveillance, Epidemiology, and End Resultsâ€“Medicare. Journal of Clinical Oncology, 2001, 19, 3712-3718.	0.8	147
40	Physician Visits Prior to Treatment for Clinically Localized Prostate Cancer. Archives of Internal Medicine, 2010, 170, 440.	4.3	145
41	Comparison of Clinicopathologic Features and Survival of Histopathologically Amelanotic and Pigmented Melanomas. JAMA Dermatology, 2014, 150, 1306.	2.0	142
42	Treatment allocation methods in clinical trials: A review. Statistics in Medicine, 1985, 4, 129-144.	0.8	137
43	The Association of Patients' Socioeconomic Characteristics with the Length of Hospital Stay and Hospital Charges within Diagnosis-Related Groups. New England Journal of Medicine, 1988, 318, 1579-1585.	13.9	134
44	Adherence to Surveillance Among Patients With Superficial Bladder Cancer. Journal of the National Cancer Institute, 2003, 95, 588-597.	3.0	127
45	An Assessment of Publication Bias Using a Sample of Published Clinical Trials. Journal of the American Statistical Association, 1989, 84, 381-392.	1.8	118
46	Two-Stage Designs for Gene-Disease Association Studies with Sample Size Constraints. Biometrics, 2004, 60, 589-597.	0.8	115
47	Construction of Receiver Operating Characteristic Curves when Disease Verification Is Subject to Selection Bias. Medical Decision Making, 1984, 4, 151-164.	1.2	111
48	Population-Based Study of Natural Variation in the Melanocortin-1 Receptor Gene and Melanoma. Cancer Research, 2006, 66, 9330-9337.	0.4	108
49	Ambient UV, personal sun exposure and risk of multiple primary melanomas. Cancer Causes and Control, 2007, 18, 295-304.	0.8	106
50	Two-Stage Designs for Gene-Disease Association Studies. Biometrics, 2002, 58, 163-170.	0.8	105
51	The Prevalence of CDKN2A Germ-Line Mutations and Relative Risk for Cutaneous Malignant Melanoma: An International Population-Based Study. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1520-1525.	1.1	105
52	Characterization ofBRCA1andBRCA2deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. Human Mutation, 2010, 31, E1200-E1240.	1.1	103
53	Risk of Asynchronous Contralateral Breast Cancer in Noncarriers of BRCA1 and BRCA2 Mutations With a Family History of Breast Cancer: A Report From the Women's Environmental Cancer and Radiation Epidemiology Study. Journal of Clinical Oncology, 2013, 31, 433-439.	0.8	101
54	A measure to aid in the interpretation of published clinical trials. Statistics in Medicine, 1985, 4, 1-9.	0.8	98

#	Article	IF	Citations
55	Methodology for Evaluating the Incidence of Second Primary Cancers with Application to Smoking-relted Cancers from the Surveillance, Epidmiology, and End Results (SEER) Program. American Journal of Epidemiology, 1995, 142, 653-665.	1.6	96
56	Comparing tumour staging and grading systems: a case study and a review of the issues, using thymoma as a model. Statistics in Medicine, 2000, 19, 1997-2014.	0.8	94
57	Polymorphisms in nucleotide excision repair genes and risk of multiple primary melanoma: the Genes Environment and Melanoma Study. Carcinogenesis, 2006, 27, 610-618.	1.3	92
58	Cystectomy for muscle-invasive bladder cancer: Patterns and outcomes of care in the medicare population. Urology, 2005, 65, 1118-1125.	0.5	86
59	The Use of Ambulatory Testing in Prepaid and Fee-for-Service Group Practices. New England Journal of Medicine, 1986, 314, 1089-1094.	13.9	84
60	Sun protection and skin selfâ€examination in melanoma survivors. Psycho-Oncology, 2009, 18, 1106-1115.	1.0	82
61	An efficient basket trial design. Statistics in Medicine, 2017, 36, 1568-1579.	0.8	82
62	Measuring Complications of Cancer Treatment Using the SEER-Medicare Data. Medical Care, 2002, 40, IV-62-IV-68.	1.1	80
63	Attribution of Deaths Following Cancer Treatment. Journal of the National Cancer Institute, 2002, 94, 1044-1045.	3.0	78
64	Participation of Community Hospitals in Clinical Trials. New England Journal of Medicine, 1982, 306, 1076-1080.	13.9	76
65	The influence of uninterpretability on the assessment of diagnostic tests. Journal of Chronic Diseases, 1986, 39, 575-584.	1.3	74
66	Rare germline mutations inPALB2and breast cancer risk: A population-based study. Human Mutation, 2012, 33, 674-680.	1.1	74
67	On inferences from Wei's biased coin design for clinical trials. Biometrika, 1990, 77, 467-473.	1.3	73
68	Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: A WECARE Study Report. European Journal of Cancer, 2013, 49, 2979-2985.	1.3	72
69	Diverse prognosis in metastatic breast cancer: Who should be offered alternative initial therapies?. Breast Cancer Research and Treatment, 1989, 13, 33-38.	1.1	69
70	A design for cancer caseâ€“control studies using only incident cases: experience with the GEM study of melanoma. International Journal of Epidemiology, 2006, 35, 756-764.	0.9	67
71	Comparing ROC curves derived from regression models. Statistics in Medicine, 2013, 32, 1483-1493.	0.8	62
72	Vitamin D receptor polymorphisms in patients with cutaneous melanoma. International Journal of Cancer, 2012, 130, 405-418.	2.3	61

#	Article	IF	Citations
73	Reporting Participation in Case-Control Studies. Epidemiology, 2002, 13, 123-126.	1.2	57
74	Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer. Breast Cancer Research and Treatment, 2010, 123, 491-498.	1.1	57
75	DNA Damage and Repair Capacity in Patients With Lung Cancer: Prediction of Multiple Primary Tumors. Journal of Clinical Oncology, 2008, 26, 3560-3566.	0.8	56
76	Vitamin D receptor polymorphisms and survival in patients with cutaneous melanoma: a population-based study. Carcinogenesis, 2016, 37, 30-38.	1.3	54
77	Random Effects Models for Combining Results from Controlled and Uncontrolled Studies in a Meta-Analysis. Journal of the American Statistical Association, 1994, 89, 1523-1527.	1.8	52
78	CDKN2A Germline Mutations in Individuals with Cutaneous Malignant Melanoma. Journal of Investigative Dermatology, 2007, 127, 1234-1243.	0.3	50
79	Familial aggregation of melanoma risks in a large population-based sample of melanoma cases. Cancer Causes and Control, 2004, 15, 957-965.	0.8	47
80	A metastasis or a second independent cancer? Evaluating the clonal origin of tumors using array copy number data. Statistics in Medicine, 2010, 29, 1608-1621.	0.8	46
81	Associations of Cumulative Sun Exposure and Phenotypic Characteristics with Histologic Solar Elastosis. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2932-2941.	1.1	45
82	Clinicopathologic Features of Incident and Subsequent Tumors in Patients with Multiple Primary Cutaneous Melanomas. Annals of Surgical Oncology, 2012, 19, 1024-1033.	0.7	45
83	Properties of analysis methods that account for clustering in volumeâ€“outcome studies when the primary predictor is cluster size. Statistics in Medicine, 2007, 26, 2017-2035.	0.8	42
84	Risk of Non-Melanoma Cancers in First-Degree Relatives of CDKN2A Mutation Carriers. Journal of the National Cancer Institute, 2012, 104, 953-956.	3.0	42
85	Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions. Breast Cancer Research, 2012, 14, R103.	2.2	38
86	Clonality: an R package for testing clonal relatedness of two tumors from the same patient based on their genomic profiles. Bioinformatics, 2011, 27, 1698-1699.	1.8	37
87	Contralateral breast cancers: Independent cancers or metastases?. International Journal of Cancer, 2018, 142, 347-356.	2.3	37
88	Inherited Genetic Variants Associated with Occurrence of Multiple Primary Melanoma. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 992-997.	1.1	36
89	<scp>MITF</scp> E318K's effect on melanoma risk independent of, but modified by, other risk factors. Pigment Cell and Melanoma Research, 2014, 27, 485-488.	1.5	35
90	Clonal relationships between lobular carcinoma in situ and other breast malignancies. Breast Cancer Research, 2016, 18, 66.	2.2	32

#	Article	IF	Citations
91	Statistical Tests for Clonality. Biometrics, 2007, 63, 522-530.	0.8	31
92	Relationship between Germline MC1R Variants and BRAF-Mutant Melanoma in a North Carolina Population-Based Study. Journal of Investigative Dermatology, 2010, 130, 1463-1465.	0.3	30
93	Sun exposure, vitamin D receptor polymorphisms FokI and BsmI and risk of multiple primary melanoma. Cancer Epidemiology, 2011, 35, e105-e110.	0.8	28
94	Association of Interferon Regulatory Factor-4 Polymorphism rs12203592 With Divergent Melanoma Pathways. Journal of the National Cancer Institute, 2016, 108, djw004.	3.0	28
95	Evaluation of the Clonal Origin of Multiple Primary Melanomas Using Molecular Profiling. Journal of Investigative Dermatology, 2009, 129, 1972-1982.	0.3	27
96	Inherited variation at MC1R and ASIP and association with melanomaâ€specific survival. International Journal of Cancer, 2015, 136, 2659-2667.	2.3	27
97	A conceptual and methodological framework for investigating etiologic heterogeneity. Statistics in Medicine, 2013, 32, 5039-5052.	0.8	26
98	Sun Exposure and Melanoma Survival: A GEM Study. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2145-2152.	1.1	26
99	Using the Lorenz Curve to Characterize Risk Predictiveness and Etiologic Heterogeneity. Epidemiology, 2016, 27, 531-537.	1.2	26
100	Familial aggregation of melanoma risks in a large population-based sample of melanoma cases. Cancer Causes and Control, 2004, 15, 957-965.	0.8	26
101	Detecting and Exploiting Etiologic Heterogeneity in Epidemiologic Studies. American Journal of Epidemiology, 2012, 176, 512-518.	1.6	24
102	An Assessment of Publication Bias Using a Sample of Published Clinical Trials. , 0, .		24
103	Taking Stock of Volume-Outcome Studies. Journal of Clinical Oncology, 2003, 21, 393-394.	0.8	23
104	Using somatic mutation data to test tumors for clonal relatedness. Annals of Applied Statistics, 2015, 9, 1533-1548.	0.5	23
105	Variants in autophagyâ€related genes and clinical characteristics in melanoma: a populationâ€based study. Cancer Medicine, 2016, 5, 3336-3345.	1.3	23
106	A strategy for distinguishing optimal cancer subtypes. International Journal of Cancer, 2011, 129, 931-937.	2.3	22
107	Inherited Variation at MC1R and Histological Characteristics of Primary Melanoma. PLoS ONE, 2015, 10, e0119920.	1.1	22
108	The use of hierarchical models for estimating relative risks of individual genetic variants: An application to a study of melanoma. Statistics in Medicine, 2008, 27, 1973-1992.	0.8	20

#	Article	IF	Citations
109	Hierarchical Modeling for Estimating Relative Risks of Rare Genetic Variants: Properties of the Pseudo-Likelihood Method. Biometrics, 2011, 67, 371-380.	0.8	20
110	Association of Incident Amelanotic Melanoma With Phenotypic Characteristics, MC1R Status, and Prior Amelanotic Melanoma. JAMA Dermatology, 2017, 153, 1026.	2.0	19
111	Systematic reviews of diagnostic accuracy studies require study by study examination: first for heterogeneity, and then for sources of heterogeneity. Journal of Clinical Epidemiology, 2005, 58, 865-866.	2.4	18
112	HER2 codon 655 polymorphism and breast cancer: results from kin-cohort and case?control analyses. Breast Cancer Research and Treatment, 2005, 89, 309-312.	1.1	17
113	Evaluating Cancer Epidemiologic Risk Factors Using Multiple Primary Malignancies. Epidemiology, 2010, 21, 366-372.	1.2	16
114	A comparison of statistical methods for the study of etiologic heterogeneity. Statistics in Medicine, 2017, 36, 4050-4060.	0.8	16
115	MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort. The Lancet Child and Adolescent Health, 2019, 3, 332-342.	2.7	16
116	Assessment of rare BRCA1 and BRCA2 variants of unknown significance using hierarchical modeling. Genetic Epidemiology, 2011, 35, 389-397.	0.6	15
117	Identifying Etiologically Distinct Subâ€Types of Cancer: A Demonstration Project Involving Breast Cancer. Cancer Medicine, 2015, 4, 1432-1439.	1.3	15
118	The Mammography Controversy. Oncologist, 2002, 7, 174-176.	1.9	14
119	Testing Clonal Relatedness of Tumors Using Array Comparative Genomic Hybridization: A Statistical Challenge. Clinical Cancer Research, 2010, 16, 1358-1367.	3.2	14
120	Kin-cohort evaluation of relative risks of genetic variants. Genetic Epidemiology, 2003, 24, 220-229.	0.6	13
121	The interaction between vitamin D receptor polymorphisms and sun exposure around time of diagnosis influences melanoma survival. Pigment Cell and Melanoma Research, 2018, 31, 287-296.	1.5	13
122	There is still a place for significance testing in clinical trials. Clinical Trials, 2019, 16, 223-224.	0.7	13
123	Comparison of Properties of Tests for Assessing Tumor Clonality. Biometrics, 2008, 64, 1018-1022.	0.8	12
124	Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE study. Cancer Causes and Control, 2010, 21, 839-846.	0.8	12
125	Genomic investigation of etiologic heterogeneity: methodologic challenges. BMC Medical Research Methodology, 2014, 14, 138.	1.4	12
126	THE ROLE OF META-ANALYSIS IN MONITORING CLINICAL TRIALS. , 1996, 15, 1299-1306.		11

#	Article	IF	Citations
127	MC1R genotype may modify the effect of sun exposure on melanoma risk in the GEM study. Cancer Causes and Control, 2010, 21, 2137-2147.	0.8	11
128	â€œRight to Tryâ€•laws. Clinical Trials, 2014, 11, 519-520.	0.7	11
129	Nevus count associations with pigmentary phenotype, histopathological melanoma characteristics and survival from melanoma. International Journal of Cancer, 2016, 139, 1217-1222.	2.3	11
130	Associations of MC1R Genotype and Patient Phenotypes with BRAF and NRAS Mutations in Melanoma. Journal of Investigative Dermatology, 2017, 137, 2588-2598.	0.3	11
131	A New Strategy for Evaluating the Impact of Epidemiologic Risk Factors for Cancer with Application to Melanoma. Journal of the American Statistical Association, 1998, 93, 415-426.	1.8	10
132	Meta-analysis methods for diagnostic accuracy. Journal of Clinical Epidemiology, 2008, 61, 1081-1082.	2.4	10
133	Using somatic variant richness to mine signals from rare variants in the cancer genome. Nature Communications, 2019, 10, 5506.	5.8	10
134	Properties of A Nonparametric Test for Early Comparison of Treatments in Clinical Trials in the Presence of Surrogate Endpoints. Biometrics, 1999, 55, 1171-1176.	0.8	9
135	Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes. Journal of Investigative Dermatology, 2018, 138, 2398-2404.	0.3	9
136	Disenrollment From Medicare Managed Care Among Beneficiaries With and Without a Cancer Diagnosis. Journal of the National Cancer Institute, 2008, 100, 1013-1021.	3.0	8
137	Ethical concerns about adaptive randomization. Clinical Trials, 2015, 12, 101-101.	0.7	8
138	No association between prediagnosis exercise and survival in patients with highâ€risk primary melanoma: A populationâ€based study. Pigment Cell and Melanoma Research, 2017, 30, 424-427.	1.5	8
139	Estimating the Probability of Clonal Relatedness of Pairs of Tumors in Cancer Patients. Biometrics, 2018, 74, 321-330.	0.8	8
140	Mining mutation contexts across the cancer genome to map tumor site of origin. Nature Communications, 2021, 12, 3051.	5.8	8
141	Interaction of CDKN2A and Sun Exposure in the Etiology of Melanoma in the General Population. Journal of Investigative Dermatology, 2011, 131, 2500-2503.	0.3	7
142	Testing the incremental predictive accuracy of new markers. Clinical Trials, 2013, 10, 690-692.	0.7	7
143	Defining Cancer Subtypes With Distinctive Etiologic Profiles: An Application to the Epidemiology of Melanoma. Journal of the American Statistical Association, 2017, 112, 54-63.	1.8	7
144	Examining the common aetiology of serous ovarian cancers and basal-like breast cancers using double primaries. British Journal of Cancer, 2017, 116, 1088-1091.	2.9	7

#	Article	IF	Citations
145	Zero tolerance for acronyms. Clinical Trials, 2017, 14, 561-562.	0.7	7
146	Random Effects Models for Combining Results from Controlled and Uncontrolled Studies in a Meta-Analysis. , 0, .		7
147	Justifying the Choice of Endpoints for Clinical Trials. Journal of the National Cancer Institute, 2013, 105, 1594-1595.	3.0	6
148	Association of Known Melanoma Risk Factors with Primary Melanoma of the Scalp and Neck. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2203-2210.	1.1	6
149	Evidence for Etiologic Subtypes of Breast Cancer in the Carolina Breast Cancer Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1784-1791.	1.1	5
150	Using the â€œHiddenâ€•genome to improve classification of cancer types. Biometrics, 2021, 77, 1445-1455.	0.8	5
151	Comment on â€œThe Predictive Capacity of Personal Genome Sequencingâ€• Science Translational Medicine, 2012, 4, 135le3; author reply 135lr3.	5.8	4
152	Testing clonal relatedness of two tumors from the same patient based on their mutational profiles: update of the Clonality R package. Bioinformatics, 2019, 35, 4776-4778.	1.8	4
153	Validation of a Population-Based Data Source to Examine National Cancer Clinical Trial Participation. JAMA Network Open, 2022, 5, e223687.	2.8	4
154	A Phase I Clinical and Pharmacokinetic Study of Carboplatin and Autologous Bone Marrow Support. Journal of Clinical Oncology, 1989, 7, 1177-1177.	0.8	3
155	In Defense of P Values. JNCI Cancer Spectrum, 2020, 4, pkaa012.	1.4	3
156	The costs of cancer drugs. Clinical Trials, 2020, 17, 118-118.	0.7	3
157	Optimized variable selection via repeated data splitting. Statistics in Medicine, 2020, 39, 2167-2184.	0.8	3
158	Comparison of community pathologists with expert dermatopathologists evaluating Breslow thickness and histopathologic subtype in a large international population-based study of melanoma. JAAD International, 2021, 4, 25-27.	1.1	3
159	RE: â€œA MULTINOMIAL REGRESSION APPROACH TO MODEL OUTCOME HETEROGENEITYâ€• American Journal of Epidemiology, 2018, 187, 1129-1130.	1.6	2
160	An EM algorithm to improve the estimation of the probability of clonal relatedness of pairs of tumors in cancer patients. BMC Bioinformatics, 2019, 20, 555.	1.2	2
161	Testing tumors from different anatomic sites for clonal relatedness using somatic mutation data. Biometrics, 2021, 77, 283-292.	0.8	2
162	Disease-Associated Risk Variants in ANRIL Are Associated with Tumor-Infiltrating Lymphocyte Presence in Primary Melanomas in the Population-Based GEM Study. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2309-2316.	1.1	2

#	Article	IF	Citations
163	Letter to the Editor of Biometrics. Biometrics, 2007, 63, 964-965.	0.8	1
164	Expedited approval programs at the Food and Drug Administration. Clinical Trials, 2018, 15, 217-218.	0.7	1
165	Inherited Melanoma Risk Variants Associated with Histopathologically Amelanotic Melanoma. Journal of Investigative Dermatology, 2020, 140, 918-922.e7.	0.3	1
166	Differences in Melanoma Between Canada and New South Wales, Australia: A Population-Based Genes, Environment, and Melanoma (GEM) Study. JID Innovations, 2021, 1, 100002.	1.2	1
167	Validity of a method for identifying disease subtypes that are etiologically heterogeneous. Statistical Methods in Medical Research, 2021, 30, 2045-2056.	0.7	1
168	Exome-Wide Pan-Cancer Analysis of Germline Variants in 8,719 Individuals Finds Little Evidence of Rare Variant Associations. Human Heredity, 2021, 86, 34-44.	0.4	1
169	Association of Melanoma-Risk Variants with Primary Melanoma Tumor Prognostic Characteristics and Melanoma-Specific Survival in the GEM Study. Current Oncology, 2021, 28, 4756-4771.	0.9	1
170	Separate Estimation of Primary and Secondary Cancer Preventive Impact: Analysis of a Case-Control Study of Skin Self-Examination and Melanoma. Journal of the American Statistical Association, 1996, 91, 1381-1387.	1.8	0
171	Editorial transition. Clinical Trials, 2014, 11, 5-6.	0.7	0
172	Editorial. Clinical Trials, 2016, 13, 573-573.	0.7	0
173	Editorial. Clinical Trials, 2016, 13, 371-371.	0.7	0
174	Patterns and sources of information about family melanoma risk among melanoma survivors. Melanoma Management, 2016, 3, 105-111.	0.1	0
175	Editorial. Clinical Trials, 2019, 16, 446-446.	0.7	0
176	Relationship of Chromosome Arm 10q Variants toÂOccurrence of Multiple Primary Melanoma in theÂPopulation-Based Genes, Environment, andÂMelanoma (GEM) Study. Journal of Investigative Dermatology, 2019, 139, 1410-1412.	0.3	0
177	Editorial: Clinical trial design in the era of COVID-19. Clinical Trials, 2020, 17, 465-466.	0.7	0
178	Human genes differ by their UV sensitivity estimated through analysis of UVâ€induced silent mutations in melanoma. Human Mutation, 2020, 41, 1751-1760.	1.1	0
179	Clinical trials in Russia. Clinical Trials, 2021, 18, 267-268.	0.7	0
180	Adapting an Undergraduate Summer Internship to a Virtual Format: Implementing a Mentored Cancer Research Experience to Meet Rising Demand for Flexible Learning Environments. Journal of Cancer Education, 2022, , 1.	0.6	0

#	Article	IF	Citations
181	Evolving challenges in clinical trials design. Clinical Trials, 2022, 19, 237-238.	0.7	0